In This Story
Anavex Life Sciences Corp. (AVXL) has submitted its Form 10-K filing for the fiscal year ended September 30, 2024.
The filing details Anavex's ongoing development of therapeutics for central nervous system diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. The company is focused on precision medicine approaches and has several compounds in different stages of clinical trials.
Anavex reported a net loss of $43.0 million for the year, compared to a net loss of $47.5 million in the previous year. The decrease in net loss is attributed primarily to reduced research and development expenses.
Research and development expenses for the year were $41.8 million, a decrease from $43.7 million in the prior year. This decrease was due to the completion of certain clinical trials and a reduction in share-based compensation expenses.
General and administrative expenses also decreased to $11.0 million from $12.0 million, largely due to a reduction in share-based compensation charges.
The company had $132.2 million in cash and cash equivalents as of September 30, 2024, down from $151.0 million the previous year. Anavex anticipates using these funds to advance its clinical programs.
Anavex's pipeline includes ANAVEX®2-73 and ANAVEX®3-71, which are being developed for various neurodegenerative and neurodevelopmental disorders. The company is also exploring potential applications for these compounds in other indications.
The company continues to receive support from the Australian government's research and development tax incentive program, contributing $2.3 million in income for the fiscal year.
Anavex has a purchase agreement with Lincoln Park Capital Fund, LLC, allowing it to sell up to $150 million in common stock over a three-year period. As of September 30, 2024, $110.8 million remained available under this agreement.
The company is involved in several legal proceedings, including shareholder class action complaints related to disclosures about clinical trials for ANAVEX®2-73 in Rett syndrome. Anavex believes these lawsuits are without merit and is seeking their dismissal.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the Anavex Life Sciences Corp. annual 10-K report dated December 23, 2024. To report an error, please email earnings@qz.com.